Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis

References

• Van Der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van Den Bosch F, Sepriano A, et al. Update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2016;2017:1–14.
   Google Scholar
• Toussirot É. Biologics in spondyloarthritis: TNFα inhibitors and other agents. Immunotherapy 2015;7:669–81.
   PubMed Web of Science ®Google Scholar
• Navarro-Compán V, Plasencia-Rodríguez C, De Miguel E, Diaz Del Campo P, Balsa A, Gratacós J. Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open 2017;3:e000524.
   PubMed Web of Science ®Google Scholar
• Patil A, Upadhyaya S, Dawar R, Dadhaniya N, Sood I, Gupta SJ, et al. Anti-drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as-needed infliximab treatment. Int J Rheum Dis 2019 Sep;22:1638–43.
   PubMed Web of Science ®Google Scholar
• Lozano MJF, Giménez RS, Fidalgo SS. Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature. Br J Clin Pharmacol 2019;85:2264–79.
   PubMed Web of Science ®Google Scholar
• Mulleman D, Balsa A. Adalimumab concentration-based tapering strategy: as good as the recommended dosage. Ann Rheum Dis 2018;77:473–5.
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:493–507.
   PubMed Web of Science ®Google Scholar
• Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012;91:635–46.
   PubMed Web of Science ®Google Scholar
• Teresa J, Chamaida P-R, Ana M-F, Victoria N-C, Theo R, Annick V, et al. Predictive value of serum infliximab levels at induction phase in rheumatoid arthritis patients. Open Rheumatol J 2017;11:75–87.
   PubMedGoogle Scholar
• Martínez-Feito A, Plasencia-Rodriguez C, Navarro-Compán V, Jurado T, Kneepkens EL, Wolbink GJ, et al. Optimal concentration range of golimumab in patients with axial spondyloarthritis. Clin Exp Rheumatol 2018;36:110–14.
   PubMed Web of Science ®Google Scholar
• Pouw MF, Krieckaert CL, Nurmohamed MT, Van Der Kleij D, Aarden L, Rispens T, et al. Key findings towards optimising adalimumab treatment: the concentration–effect curve. Ann Rheum Dis 2015;74:513–8.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol 2016;51:241–51.
   PubMed Web of Science ®Google Scholar
• L ’Ami MJ, Krieckaert CL, Nurmohamed MT, Van Vollenhoven RF, Rispens T, Boers M, et al. Clinical and epidemiological research Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis 2018;77:484–7.
   PubMed Web of Science ®Google Scholar
• Ducourau E, Mulleman D, Paintaud G, Miow Lin DC, Lauféron F, Ternant D, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011;13:R105.
   PubMed Web of Science ®Google Scholar
• Plasencia C, Pascual-Salcedo D, Nuño L, Bonilla G, Villalba A, Peiteado D, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012;71:1955–60.
   PubMed Web of Science ®Google Scholar
• Gratacós J, Díaz Del Campo Fontecha P, Fernández-Carballido C, Juanola Roura X, Linares Ferrando LF, De Miguel Mendieta E, et al. Recommendations by the Spanish Society of rheumatology on the use of biological therapies in axial spondyloarthritis. Reumatol Clin 2018;14:320–33.
   PubMed Web of Science ®Google Scholar
• Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47–53.
   PubMed Web of Science ®Google Scholar
• Machado PM, Landewé R, Van der Heijde D. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis 2018;77:1539–40.
   PubMed Web of Science ®Google Scholar
• Pascual-Salcedo D, Plasencia C, Ramiro S, Nuñ OL, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50:1445–52.
   PubMed Web of Science ®Google Scholar
• Ducourau E, Ternant D, Lequerré T, Fuzibet P, Le Loët X, Watier H, et al. Towards an individualised target concentration of adalimumab in rheumatoid arthritis. Ann Rheum Dis 2014;73:1428–9.
   PubMed Web of Science ®Google Scholar
• William E, Clair S, Wagner CL, Fasanmade AA, Wang B, Schaible T, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451–9.
   PubMedGoogle Scholar
• Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut 2015;64:1539–45.
   PubMed Web of Science ®Google Scholar
• De Vries MK, Wolbink G, Stapel SO. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66:1252–4.
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012;71:1914–15.
   PubMed Web of Science ®Google Scholar
• Vogelzang EH, Pouw MF, Nurmohamed M, Kneepkens EL, Rispens T, Wolbink GJ, et al. Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs. Ann Rheum Dis 2015;74:474–5.
   PubMed Web of Science ®Google Scholar
• Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, Martínez-Feito A, Jochems A, Kneepkens EL, et al. Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. Arthritis Res Ther 2019;21:1–7.
   PubMed Web of Science ®Google Scholar
• Jani M, Chinoy H, Warren RB, Griffiths CEM, Plant D, Fu B, et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol 2015;67:2011–9.
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782–9.
   PubMed Web of Science ®Google Scholar
• Van Den Bemt BJF, Den Broeder AA, Wolbink G, Van Den Maas A, Hekster YA, Van Riel PLCM, et al. The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-) response to infliximab in rheumatoid arthritis. Br J Clin Pharmacol 2013;76:939–45.
   PubMed Web of Science ®Google Scholar
• Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open 2015;1:1–11.
   Web of Science ®Google Scholar
• Sieper J, Landewé R, Magrey M, Anderson JK, Zhong S, Wang X, et al. Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. RMD Open 2019;5:e000917.
   PubMed Web of Science ®Google Scholar
• Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008;67:511–7.
   PubMed Web of Science ®Google Scholar
• De Vries MK, Van Eijk IC, Van Der Horst-Bruinsma IE, Peters MJL, Nurmohamed MT, Dijkmans BAC, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Care Res 2009;61:1484–90.
   Web of Science ®Google Scholar
• Lorenzin M, Ortolan A, Frallonardo P, Oliviero F, Punzi L, Ramonda R. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord 2015;16:10–17.
   PubMed Web of Science ®Google Scholar
• Heinonen AV, Aaltonen KJ, Joensuu JT, Lähteenmäki JP, Pertovaara MI, Romu MK, et al. Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study. J Rheumatol 2015;42:2339–46.
   PubMed Web of Science ®Google Scholar
• Ducourau E, Rispens T, Samain M, Dernis E, Le Guilchard F, Andras L, et al. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open 2020;6:e001047.
   PubMed Web of Science ®Google Scholar
• Lie E, Kristensen LE, Forsblad-d’Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis 2015 Jun;74:970–8.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AGR, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2013 Jul;72:1149–55.
   PubMed Web of Science ®Google Scholar
• Chu Miow Lin D, Mulleman D, Azzopardi N, Griffoul-Espitalier I, Valat J-P, Paintaud G, et al. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis. Scand J Rheumatol 2010;39:97–8.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Schöls M, Braun J, Dougados M, Gerald OF, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018;77:3–17.
   PubMed Web of Science ®Google Scholar